David J. Arthur is CEO at Salarius Pharmaceuticals, Inc. (SLRX). They have made 5 open-market trades across 1 company since 2020, most recently 2023-02-13.
CIK 0001769331
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
5 open-market purchases totalling $124K since 2020, never a sale. Across 5 scored buys the stock is down 19.6% at ninety days, and 18.0 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| SLRX | 48,019 | $40K |
Shares reported on the most recent Form 4, priced at the 2023-02-15 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 20% | 20% | 40% |
| Avg Move | -3.1% | -5.0% | -19.6% |
| Alpha | -2.8% | +0.0% | -18.0% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| SLRX | BUY | 2022-05-26 | 2022-05-31 | $0.18 | $8K | -2.0% | +0.0% | +2.5% |
| SLRX | BUY | 2022-03-03 | 2022-03-09 | $0.39 | $109K | -11.5% | -14.6% | -57.1% |
| SLRX | BUY | 2021-08-17 | 2021-08-17 | $0.90 | $4K | +11.1% | +13.3% | -15.7% |
| SLRX | BUY | 2020-08-19 | 2020-08-20 | $1.01 | $1K | -8.6% | -14.8% | -29.6% |
| SLRX | BUY | 2020-02-11 | 2020-02-12 | $1.15 | $3K | -4.7% | -8.9% | +1.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.